Top

Published in:

01-07-2014 | Letter to the Editor

Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells

Authors: Bo Yang, Hai-tao Wang, Li-li Cai, Yu Zhao, Xiao-hua Chi, Hong-li Zhu, Hai-hong Ran, Yang Yang, Rui-li Yu, Song-wei Li, Xue-chun Lu

Published in: Annals of Hematology | Issue 7/2014

Excerpt

Dear Editor, …

Lu XC, Yang B, Yu RL, Chi XH, Tuo S, Tuo CW, Zhu HL, Wang Y, Jiang CG, Fu XB, Yang Y, Liu Y, Yao SQ, Dai HR, Cai L, Li BJ, Han WD (2012) Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys 62:257–265PubMedCrossRef

Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803PubMedCrossRef

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987–1996PubMedCrossRef

Yang B, Lu XC, Yu RL, Chi XH, Liu Y, Wang Y, Dai HR, Zhu HL, Cai LL, Han WD (2012) Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 30:115–122PubMedCrossRef

Liu Y, Bao EN, Yang B, Lu XC, Zhu HL, Han WD, Wang Y, Dai HR, Yao SQ (2011) Clinical study of autologous cytokine induced killer cell infusion treating for elderly patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 19:787–792PubMed

Schanz J, Jung H, Wörmann B, Gassmann W, Petersen T, Hinke A, Haase D (2009) Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. Leuk Res 33:1183–1188PubMedCrossRef

Kashiwakura I, Murakami M, Inanami O, Hayase Y, Takahashi TA, Kuwabara M, Takagi Y (2002) Effects of amifostine on the proliferation and differentiation of megakaryocytic progenitor cells. Eur J Pharmacol 437:19–25PubMedCrossRef

Avilés A, Díaz-Maqueo JC, Talavera A, García EL, Guzmán R, Nambo MJ (1997) BM protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer 33:1323–1325PubMedCrossRef

Title: Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells
Authors: Bo Yang
Hai-tao Wang
Li-li Cai
Yu Zhao
Xiao-hua Chi
Hong-li Zhu
Hai-hong Ran
Yang Yang
Rui-li Yu
Song-wei Li
Xue-chun Lu
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 7/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-013-1946-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2014

Inhibitor of differentiation 1 is a candidate prognostic marker in multicentric Castleman’s disease

Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)

Plasma cell myeloma with mature lymphoproliferative disease-like morphology: an unusual case

Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera

The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma

G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials